Key facts
- Rarity (Biotechnology)’s last known valuation is $10.0M (Oct 2025).
- It has raised $4.6M; the latest was Seed Round ($4.6M) in Oct 2025.
- Notable investors include Steve Oliveira.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Rarity (Biotechnology)
- ·The full record, as it builds
Funding rounds
No funding rounds for Rarity (Biotechnology) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Rarity (Biotechnology)
Operator of a public benefit biotech company intended to develop accessible and affordable gene therapies for rare diseases. The company offers life-saving gene therapies that target the root causes of rare genetic disorders, enabling customers to access potentially curative treatments that are both affordable and designed to restore normal biological function.
- Sector
- Healthcare
- HQ
- Los Angeles, CA, United States
- Founded
- 2023
- Employees
- 5
- Website
- raritypbc.com/
- Ownership
- Privately Held (backing)
Rarity (Biotechnology) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Rarity (Biotechnology) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Rarity (Biotechnology) in its N-PORT filings yet. We sweep new filings monthly.